Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

Haleon Plc reports strong Q3 organic revenue growth, guidance reaffirmed

Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

FDA accepted New Drug Application for GSK’s Gepotidacin

GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...

GSK plc to seek dismissal of upcoming Wilson case in Florida

GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...

GSK wins jury verdict in Illinois ranitidine cancer case

GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

GSK and CureVac to restructure collaboration into new licensing agreement

GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...

GSK’s Omjjara approved in Japan for treatment of myelofibrosis

GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
Search

Funds

Health

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...

Haleon Plc reports strong Q3 organic revenue growth, guidance reaffirmed

Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

FDA accepted New Drug Application for GSK’s Gepotidacin

GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...

GSK plc to seek dismissal of upcoming Wilson case in Florida

GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...

GSK wins jury verdict in Illinois ranitidine cancer case

GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

GSK and CureVac to restructure collaboration into new licensing agreement

GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...

GSK’s Omjjara approved in Japan for treatment of myelofibrosis

GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
Search

Funds

Health

FTSE 100

Funds